{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:01:00Z","timestamp":1775584860123,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117082","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T22:16:35Z","timestamp":1732054595000},"page":"117082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold"],"prefix":"10.1016","volume":"282","author":[{"given":"Wenxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zibin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqian","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117082_bib1","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1097\/HEP.0000000000000696","article-title":"Reply: a multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.117082_bib2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.117082_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2024.117082_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.117082_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2024.117082_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112311","article-title":"Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment","volume":"197","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117082_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1358\/dof.2020.45.12.3191006","article-title":"Resmetirom Thyroid hormone receptor-\u03b2 agonist Treatment of nonalcoholic steatohepatitis","volume":"45","author":"Gras","year":"2020","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2024.117082_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117082_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117082_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.foodres.2018.06.035","article-title":"New insights into bacterial bile resistance mechanisms: the role of bile salt hydrolase and its impact on human health","volume":"112","author":"Bustos","year":"2018","journal-title":"Food Res. Int."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117082_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11892-018-1092-3","article-title":"Rethinking bile acid metabolism and signaling for type 2 diabetes treatment","volume":"18","author":"Zaborska","year":"2018","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.ejmech.2024.117082_bib12","first-page":"93","article-title":"Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system, Toxicol in Vitro","volume":"39","author":"Dash","year":"2017"},{"key":"10.1016\/j.ejmech.2024.117082_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ejmech.2024.117082_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155264","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","volume":"134","author":"Yan","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2024.117082_bib15","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1016\/j.bmcl.2008.06.073","article-title":"Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064","volume":"18","author":"Akwabi-Ameyaw","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117082_bib16","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1021\/acs.jmedchem.5b01161","article-title":"Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia","volume":"58","author":"Genin","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117082_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.117082_bib18","article-title":"EDP-305, A novel and selective farnesoid X receptor agonist, exhibits high potency and efficacy in vitro and in vivo","volume":"64","author":"Li","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.117082_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien Klin. Wochenschr."},{"key":"10.1016\/j.ejmech.2024.117082_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver Injury","volume":"10","author":"Sepe","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117082_bib21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117082_bib22","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117082_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.117082_bib24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, pharmacokinetics, pharmacodynamics, and formulation of liver-distributed farnesoid X-receptor agonist TERN-101 in healthy volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharm. Drug. Dev."},{"issue":"7887","key":"10.1016\/j.ejmech.2024.117082_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ejmech.2024.117082_bib26","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.117082_bib27","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2024.117082_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2022.02.036","article-title":"Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor","volume":"600","author":"Jiang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117082_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver Injury","volume":"10","author":"Sepe","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117082_bib30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","article-title":"Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors","volume":"98","author":"Kuzmanic","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2024.117082_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.procbio.2023.12.014","article-title":"Docking and molecular dynamic simulations of Mithramycin-A and Tolfenamic acid against Sp1 and survivin","volume":"137","author":"Lambring","year":"2024","journal-title":"Process Biochem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117082_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/md21080446","article-title":"Experimental and computational investigation of solvatochromism, tautomerism and free energy landscapes of a pyridoacridinium quaternary salt","volume":"21","author":"Gartshore","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2024.117082_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744483","article-title":"Micronized palmitoylethanolamide ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis via inhibiting inflammation and restoring autophagy","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117082_bib34","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.117082_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bcpt.13122","article-title":"Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice","volume":"124","author":"Liu","year":"2019","journal-title":"Basic Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.ejmech.2024.117082_bib36","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117082_bib37","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.117082_bib38","author":"Schr\u00f6dinger"},{"issue":"3","key":"10.1016\/j.ejmech.2024.117082_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:18:26Z","timestamp":1733516306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S0223523424009644"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117082","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117082"}}